Go Pro
→ The $15 Gold Fund That Pays Up to $1,152/Month (From Investors Alley) (Ad)tc pixel
OTCMKTS:SKVI

Skinvisible Q3 2025 Earnings Report

$0.21 0.00 (0.00%)
As of 06/26/2026
ProfileEarnings History

Skinvisible EPS Results

Actual EPS
-$0.05
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Skinvisible Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Skinvisible Announcement Details

Quarter
Q3 2025
Date
11/13/2025
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Skinvisible Earnings Headlines

SKINVISIBLE INC by Skinvisible, Inc. Insider Trading Activity | OTC:SKVI | Benzinga
May 17, 2026  |  benzinga.comhttps://www.benzinga.com/quote/SKVI/insider-trades
Skinvisible Inc.
May 11, 2026  |  marketwatch.comhttps://www.marketwatch.com/investing/stock/SKVI/financials
Trump’s secret China deal
Trump just returned from Beijing with the most powerful business delegation in American history - Elon Musk, Jensen Huang, Tim Cook, and the CEOs of BlackRock, Goldman Sachs, and CitiBank. The media covered the handshakes. But what was really being negotiated behind closed doors? Porter Stansberry has connected the Beijing trip to a landmark pact signed by 13 nations in Washington - a pact designed to cut China out of a $3 trillion investment wave tied to the most critical resource of the 21st century. His new documentary exposes the five assets at the center of it all.tc pixel
June 28 at 1:00 AM  |  Porter & Company (Ad)
Skinvisible Stock Price History
October 9, 2025  |  investing.comhttps://www.investing.com/equities/skinvisible-inc-historical-data
Ovation Science and Skinvisible Pharmaceuticals Enhance Their Strategic Partnership in the Obesity Market with Innovative Cannabinoid Delivery Technology with New Developments ...
September 19, 2025  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/OVATF/pressreleases/34883721/ovation-science-and-skinvisible-pharmaceuticals-enhance-their-strategic-partnership-in-the-obesity-market-with-innovative-cannabinoid-delivery-technology-with-new-developments-and-patent-protection/
Skinvisible Delays 10-K Filing Due to Compilation Issues
March 31, 2025  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/skinvisible-delays-10-k-filing-due-to-compilation-issues?utm_source=marketbeat.com&utm_medium=referral
See More Skinvisible Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Skinvisible? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Skinvisible and other key companies, straight to your email.

About Skinvisible

Skinvisible (OTCMKTS:SKVI), Inc., together with its subsidiaries, focuses on the development, manufacture, and sale of topical, transdermal, and mucosal polymer-based delivery system technologies and formulations for use in pharmaceutical, over-the-counter, personal skincare, and cosmetic arenas. Its non-dermatological formulations offer solutions for women's health, pain management, and other markets. The company's flagship product is Invisicare, a patented polymer delivery system technology that enhances the delivery of active ingredients for topically applied skin care products. It also develops and licenses prescription and over-the-counter products to pharmaceutical and consumer goods companies; assists pharmaceutical clients in the early development of the formulations; and provides solutions to pharmaceutical companies by reformulating their products coming off patent with a new Invisicare patent, and new product benefits and line extensions. The company was formerly known as Microbial Solutions, Inc. and changed its name to Skinvisible, Inc. in February 1999. Skinvisible, Inc. was incorporated in 1998 and is based in Las Vegas, Nevada.

View Skinvisible Profile
Earnings Tools